Publications by authors named "Alexander F A D Schauwvlieghe"

Background: Invasive aspergillosis (IA) by a triazole-resistant Aspergillus fumigatus is associated with high mortality. Real-time resistance detection will result in earlier initiation of appropriate therapy.

Methods: In a prospective study, we evaluated the clinical value of the AsperGenius polymerase chain reaction (PCR) assay in hematology patients from 12 centers.

View Article and Find Full Text PDF

Background: Oral follow-up therapy is problematic in moulds with reduced azole-susceptibility, such as azole-resistant Aspergillus fumigatus infection. Currently, only intravenous liposomal amphotericin B (L-AmB) is advocated by guidelines for the treatment of azole-resistant aspergillosis infections. Preclinical research indicates that high-dose posaconazole (HD-POS) might be a feasible option provided that high drug exposure (ie POS serum through levels >3 mg/L) can be achieved and is safe.

View Article and Find Full Text PDF
Article Synopsis
  • Aspergillus fumigatus resistance to voriconazole, a common antifungal, poses a significant risk, particularly in hematology patients, with reported mortality rates ranging from 50% to 100%.
  • A study on 129 culture-positive invasive aspergillosis cases found 20.2% were voriconazole-resistant, with most resistant strains having specific mutations.
  • The research showed that non-ICU patients with voriconazole-resistant infections had a noticeably higher mortality rate at 12 weeks compared to those with susceptible infections, highlighting the urgency of addressing this resistance problem.
View Article and Find Full Text PDF

Background: Triazole resistance is an increasing problem in invasive aspergillosis (IA). Small case series show mortality rates of 50%-100% in patients infected with a triazole-resistant Aspergillus fumigatus, but a direct comparison with triazole-susceptible IA is lacking.

Methods: A 5-year retrospective cohort study (2011-2015) was conducted to compare mortality in patients with voriconazole-susceptible and voriconazole-resistant IA.

View Article and Find Full Text PDF

Background: Invasive pulmonary aspergillosis typically occurs in an immunocompromised host. For almost a century, influenza has been known to set up for bacterial superinfections, but recently patients with severe influenza were also reported to develop invasive pulmonary aspergillosis. We aimed to measure the incidence of invasive pulmonary aspergillosis over several seasons in patients with influenza pneumonia in the intensive care unit (ICU) and to assess whether influenza was an independent risk factor for invasive pulmonary aspergillosis.

View Article and Find Full Text PDF

Patients with haematological malignancies are at risk for invasive fungal diseases (IFD). A survey was conducted in all Dutch academic haematology centres on their current diagnostic, prophylactic and therapeutic approach towards IFD in the context of azole-resistance. In all 8 centres, a haematologist and microbiologist filled in the questionnaire that focused on different subgroups of haematology patients.

View Article and Find Full Text PDF

Synopsis of recent research by authors named "Alexander F A D Schauwvlieghe"

  • - Alexander F A D Schauwvlieghe's research primarily focuses on the clinical management and implications of invasive aspergillosis, particularly regarding the detection and treatment of azole-resistant Aspergillus infections in high-risk patient populations like those with hematological malignancies.
  • - His recent study on the AsperGenius PCR assay has shown promise for real-time detection of triazole resistance, which may facilitate earlier and more effective treatment, highlighting a critical need for rapid molecular diagnostics in clinical settings.
  • - Schauwvlieghe's work also explores the alarming trends in antifungal resistance, including the prevalence of voriconazole-resistant invasive aspergillosis and its correlation with increased mortality, underscoring the necessity for updated therapeutic strategies to combat these resistant infections.